ArticleAdvanced functional materials2025
Functional hydrogel for modulating lipid droplets and neuroinflammation in head injury.
Article in Advanced functional materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DFT investigation of fluorination sites effects on the photovoltaic performance of D-π-A donor materials.Journal of molecular modeling · 2026Article
- Noble metal nanozymes: synthesis, mechanism, activity regulation and detection applications.Mikrochimica acta · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Excessive inflammatory responses following traumatic brain injury (TBI) hinder tissue healing and impair long-term functional recovery. In addition to therapeutic strategies that directly target the core pathological mechanisms of TBI, biomaterials and regenerative medicine now offer promising new avenues. Here, we report a new formulation of an injectable hydrogel based on gelatin methacryloyl (GelMA) conjugated with β-cyclodextrin (βCD), designed for implantation in TBI lesions. Compared to GelMA alone, βCD-containing hydrogels (βCD-GelMA) demonstrated a strong capacity to sequester cholesterol from cultured cells, thereby reducing lipid droplet formation and suppressing inflammatory responses. Notably, aberrant cholesterol accumulation and lipid droplet formation were observed in a mouse model of TBI, andimplantation of βCD-GelMA into the lesion area significantly reduced peak tissue cholesterol and lipid droplet levels post-injury. More importantly, βCD-GelMA mitigated gliosis, reduced inflammation and scar formation, and improved functional outcomes in the TBI model. Mechanistically, by scavenging cholesterol from injured tissue, βCD-GelMA normalized microglial lipid droplet and promoted polarization toward a less inflammatory phenotype. In summary, our study highlights the strong therapeutic potential of βCD in restoring cholesterol homeostasis and resolving lipid droplet-associated inflammation, and demonstrates that the βCD-GelMA functional hydrogel represents a promising intervention strategy for head injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.